Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Choroidal Neovascularization - Overview Choroidal Neovascularization - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Choroidal Neovascularization - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Choroidal Neovascularization - Companies Involved in Therapeutics Development F. Hoffmann-La Roche Ltd Formycon AG Iconic Therapeutics Inc Isarna Therapeutics GmbH Lupin Ltd Mabion SA NovelMed Therapeutics Inc Noxxon Pharma AG Promedior Inc Choroidal Neovascularization - Drug Profiles ACX-107 - Drug Profile Product Description Mechanism Of Action R&D Progress aflibercept biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress aflibercept biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress Antisense Oligonucleotides for Ophthalmology and Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Ayuv-4 - Drug Profile Product Description Mechanism Of Action R&D Progress Gene Therapy to Activate Calreticulin for Choroidal Neovascularization - Drug Profile Product Description Mechanism Of Action R&D Progress ICON-1 - Drug Profile Product Description Mechanism Of Action R&D Progress ISTH-0036 - Drug Profile Product Description Mechanism Of Action R&D Progress NM-9405 - Drug Profile Product Description Mechanism Of Action R&D Progress NOXD-20 - Drug Profile Product Description Mechanism Of Action R&D Progress PRM-167 - Drug Profile Product Description Mechanism Of Action R&D Progress ranibizumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress RG-7716 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule for Inflammation and Choroidal Neovascularization - Drug Profile Product Description Mechanism Of Action R&D Progress Synthetic Peptides for Age Related Macular Degeneration and Choroidal Neovascularization - Drug Profile Product Description Mechanism Of Action R&D Progress Choroidal Neovascularization - Dormant Projects Choroidal Neovascularization - Discontinued Products Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development for Choroidal Neovascularization, H1 2018 Number of Products under Development by Companies, H1 2018 Number of Products under Development by Universities/Institutes, H1 2018 Products under Development by Companies, H1 2018 Products under Development by Universities/Institutes, H1 2018 Number of Products by Stage and Target, H1 2018 Number of Products by Stage and Mechanism of Action, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018 Choroidal Neovascularization - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018 Choroidal Neovascularization - Pipeline by Formycon AG, H1 2018 Choroidal Neovascularization - Pipeline by Iconic Therapeutics Inc, H1 2018 Choroidal Neovascularization - Pipeline by Isarna Therapeutics GmbH, H1 2018 Choroidal Neovascularization - Pipeline by Lupin Ltd, H1 2018 Choroidal Neovascularization - Pipeline by Mabion SA, H1 2018 Choroidal Neovascularization - Pipeline by NovelMed Therapeutics Inc, H1 2018 Choroidal Neovascularization - Pipeline by Noxxon Pharma AG, H1 2018 Choroidal Neovascularization - Pipeline by Promedior Inc, H1 2018 Choroidal Neovascularization - Dormant Projects, H1 2018 Choroidal Neovascularization - Dormant Projects, H1 2018 (Contd..1), H1 2018 Choroidal Neovascularization - Discontinued Products, H1 2018 List of Figures Number of Products under Development for Choroidal Neovascularization, H1 2018 Number of Products under Development by Companies, H1 2018 Number of Products by Targets, H1 2018 Number of Products by Stage and Targets, H1 2018 Number of Products by Mechanism of Actions, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Stage and Routes of Administration, H1 2018 Number of Products by Molecule Types, H1 2018 Number of Products by Stage and Molecule Types, H1 2018

F. Hoffmann-La Roche Ltd Formycon AG Iconic Therapeutics Inc Isarna Therapeutics GmbH Lupin Ltd Mabion SA NovelMed Therapeutics Inc Noxxon Pharma AG Promedior Inc